New York State Common Retirement Fund Boosts Stake in Vanda Pharmaceuticals Inc. (VNDA)

New York State Common Retirement Fund grew its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 14.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,370 shares of the biopharmaceutical company’s stock after acquiring an additional 6,799 shares during the quarter. New York State Common Retirement Fund owned 0.12% of Vanda Pharmaceuticals worth $870,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Birchview Capital LP boosted its position in shares of Vanda Pharmaceuticals by 25.9% in the second quarter. Birchview Capital LP now owns 68,000 shares of the biopharmaceutical company’s stock valued at $1,108,000 after acquiring an additional 14,000 shares during the period. State of Wisconsin Investment Board bought a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $538,000. American International Group Inc. boosted its position in shares of Vanda Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after acquiring an additional 1,491 shares during the period. AJO LP boosted its position in shares of Vanda Pharmaceuticals by 94.2% in the second quarter. AJO LP now owns 541,927 shares of the biopharmaceutical company’s stock valued at $8,833,000 after acquiring an additional 262,833 shares during the period. Finally, FMR LLC boosted its position in shares of Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock valued at $22,416,000 after acquiring an additional 604,900 shares during the period. 87.01% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.com-unik.info/2017/11/06/new-york-state-common-retirement-fund-boosts-stake-in-vanda-pharmaceuticals-inc-vnda.html.

VNDA has been the subject of several research reports. Zacks Investment Research cut Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 18th. Oppenheimer Holdings, Inc. set a $21.00 price objective on Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. HC Wainwright set a $18.00 price objective on Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Piper Jaffray Companies set a $23.00 price objective on Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, BidaskClub cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $22.00.

Vanda Pharmaceuticals Inc. (VNDA) opened at $16.10 on Monday. Vanda Pharmaceuticals Inc. has a 12-month low of $12.70 and a 12-month high of $18.99.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

What are top analysts saying about Vanda Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vanda Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit